Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission.
Phase 2
Recruiting
- Conditions
- chronic myeloid leukemia
- Registration Number
- JPRN-UMIN000008999
- Lead Sponsor
- Epidemiological and Clinical Research Information Network(ECRIN)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Concurrent malignancy other than CML 2.Women who are pregnant or breastfeeding 3. A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy 4.Subjects with T315I, F317L and V299L BCR-ABL point mutations 5.Subjects with clonal evolution
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method